Very often patients receive sedative medication before a diagnostic, therapeutic, or surgical procedure to help them relax, keep them calm, and to relieve them from pain. This is called procedural sedation. During procedural (mild to moderate) sedation, a patient is first given a pain-relief medication (analgesic) and then a medication to help him/her relax and keep him/her calm (sedative). Propofol is the drug commonly used for sedation because it releases immediately into the blood stream and causes fast sedation. AQUAVAN (fospropofol disodium) is made as a slow release version of propofol, allowing for fast sedation and possibly faster recovery and discharge.

This study is intended to compare several different doses of AQUAVAN in patients having a colonoscopy in order to find the right dose that will get patients to a level of mild to moderate (procedural) sedation.

Condition	Intervention	Phase
Colonoscopy Colon Polyps Endoscopic sedation Endoscopic outcomes Endoscopy	Drug: AQUAVAN® (fospropofol disodium) Injection  Drug: Midazolam HCl	Phase II Phase III

Further Study Details: 

Primary Outcomes: 3 consecutive MOAA/S scores ≤4 after administration of sedative medication AND completing the procedure 1) without requiring the use of alternative sedative medication AND 2) without requiring manual or mechanical ventilation.
Secondary Outcomes: Pt’s rating of experience after Ready for Discharge; PI’s rating at end of procedure; % of pts. requiring alternative sedative medication; # of doses/amount of fentanyl administered; # of doses of study medication administered; Time to sedation, digital rectal examination, start of procedure, reach splenic flexure, hepatic flexure, cecum, end of procedure, and Ready for Discharge; % of pts. requiring repositioning; % of pts. whose procedures are interrupted due to inadequate sedation; Time to Ready for Discharge from end of procedure; Change from baseline DSST score over time during recovery period; Pt’s rating at 24 hour post discharge telephone survey; Duration and percent of time when a pt’s MOAA/S score is at each level between the first dose of study medications and Fully Alert and during the procedure; PI’s rating of level of sedation prior to initiation of the procedure; % of pts. with a mean MOAA/S of 2 to 4 and 0 to 1 during the procedure; MOAA/S over time
Expected Total Enrollment:  125

This is a randomized, double-blind study designed to evaluate the dose-response in the sedation success rate for 4 different initial bolus doses of AQUAVAN following pretreatment with an analgesic, fentanyl, in patients undergoing a colonoscopy. A group of patients will receive midazolam as a reference therapy.

Following completion of preprocedure assessments, patients will be randomly assigned to 1 of 5 i.v. treatment groups at an equal allocation ratio (25 patients per arm) on the day of the scheduled procedure. Randomization will be stratified by age and ASA status: AQUAVAN initial bolus dose 1: 8 mg/kg AQUAVAN initial bolus dose 2: 6.5 mg/kg AQUAVAN initial bolus dose 3: 5 mg/kg AQUAVAN initial bolus dose 4: 2 mg/kg Midazolam initial bolus dose: 0.02 mg/kg

A person skilled in airway management and authorized by the facility in which the colonoscopy is performed (such as a respiratory therapist, a study nurse, or a clinician) must be immediately available during the conduct of the study. All patients will be placed on supplemental oxygen via nasal cannula (4 L/min), and a 12-lead electrocardiogram (ECG), pulse oximeter, and blood pressure monitor prior to administration of study medication. All patients will receive an injection of analgesic pretreatment followed by the administration of sedative medication, as described below. This protocol recognizes 2 distinct phases of sedation: Sedation Initiation and Sedation Maintenance. Assessments will be made to evaluate the patients for levels of sedation, clinical benefit, and adverse events as detailed in the protocol. Blood samples will be collected for PK analysis, also detailed in the protocol.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Number of Patients/Site: Approximately 125 patients, 25 per arm, at up to 25 sites will be randomized into this study.

Study Country Location: United States

Study Population: Male and female patients aged 18 years and older and undergoing elective colonoscopy will be enrolled in the study.

Inclusion Criteria: -Patient provides signed/dated Informed Consent and Health Insurance Portability and Accountability Act of 1996 (HIPAA) authorization after receiving a full explanation of the extent and nature of the study -Patient must be at least 18 years of age at the time of screening -If female, patient must be surgically sterile, postmenopausal, or not pregnant or lactating and has been using an acceptable method of birth control for at least 1 month prior to dosing, with a negative urine pregnancy test result at screening and predose -Patient meets American Society of Anesthesiologists (ASA) Physical Classification System status of P1 to P4

Exclusion Criteria: -Patient has a history of allergic reaction or hypersensitivity to any anesthetic agent, narcotic, or benzodiazepine -Patient does not meet nils per os (NPO) status per ASA guidelines or institution’s guideline -Patient has a Mallampati Classification Score of 4; OR a Mallampati Classification Score of 3 AND athyromental distance ¡Ü4 cm, or for any other reason has a difficult airway, in the opinion of the Investigator -Patient has an abnormal, clinically significant 12-lead ECG finding at predosing period Day 0 -Patient has participated in an investigational drug study within 1 month prior to study start -Patient is unwilling to adhere to pre- and postprocedural instructions -Patient for whom the use of fentanyl is contraindicated -Patient for whom the use of midazolam HCl injection (midazolam) is contraindicated

Please refer to this study by ClinicalTrials.gov identifier  NCT00125424

Maryland
      Chevy Chase Clinical Reserach, Chevy Chase,  Maryland,  20815,  United States; Recruiting

Study chairs or principal investigators

James Jones, PharmD, MD,  Study Director,  Guilford Pharmaceuticals   

Study ID Numbers:  GPI 3000-0520
Last Updated:  August 1, 2005
Record first received:  July 29, 2005
ClinicalTrials.gov Identifier:  NCT00125424
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-02